Glaukos Corporation
GKOSGlaukos Corporation (GKOS) is a medical device company that specializes in innovative treatments for glaucoma, corneal disorders, and other ocular diseases. It is known for its development of minimally invasive devices, including the iStent trabecular micro-bypass stent, which helps lower intraocular pressure and reduces reliance on medication for glaucoma patients. The company focuses on advancing ophthalmic healthcare through novel, minimally invasive surgical solutions.
Company News
Glaukos CFO Alex Thurman sold 10,000 shares worth $1.6 million on July 9, 2026, under a pre-established Rule 10b5-1 trading plan adopted in December 2025. While insider sales can raise concerns, the non-discretionary nature of this transaction and Glaukos' strong growth outlook—including 25% projected revenue growth for 2026 and the promising E...
Abbott Laboratories and Glaukos represent two contrasting healthcare investment strategies: Abbott offers stability through diversification, strong profitability, and recent acquisitions like Exact Sciences, while Glaukos provides high-growth potential in specialized ophthalmic treatments with innovative products like iDose and Epioxa. Abbott tra...
The presbyopia market is projected to grow at a CAGR of 4.9% from 2026-2036, driven by an aging global population and expanding treatment options. The market was valued at USD 11 billion in 2025 across seven major markets, with the US accounting for 50% of the market. Multiple emerging therapies and devices are expected to enter the market, inclu...
Nicox plans to fully repay its financial debts by 2026 after successfully licensing NCX 470 globally with Kowa and Ocumension Therapeutics, with New Drug Application submissions expected in the first half of 2026 in the US and later in China.
Nicox anticipates fully repaying its financial debts in 2026 following successful NCX 470 clinical trials and global licensing deals with Kowa and Ocumension Therapeutics, with expected NDA submissions in the U.S. and China in H1 2026.
